STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

Core Viewpoint - STAAR Surgical Company did not receive the necessary stockholder votes to approve the merger agreement with Alcon, leading to the intention to terminate the merger agreement and remain a standalone company [1][2]. Company Overview - STAAR Surgical is the global leader in implantable phakic intraocular lenses (ICLs), focusing solely on ophthalmic surgery since 1982 [3]. - The company has designed, developed, manufactured, and marketed advanced Implantable Collamer® Lenses (ICLs) for over 30 years, utilizing proprietary biocompatible Collamer material [3]. - STAAR ICLs are clinically proven to provide safe long-term vision correction without the need for corneal tissue removal or the extraction of the eye's natural crystalline lens [3]. - The EVO ICL™ product line offers visual freedom through a quick, minimally invasive procedure, with over 3 million ICLs sold in more than 75 countries [3]. Strategic Direction - The CEO of STAAR expressed commitment to maximizing stockholder value and realizing the full potential of STAAR's innovative technology, emphasizing the company's competitive position and the quality of its EVO ICL technology [2]. - In the short term, the company will prioritize profitable sales growth and drive efficiencies through its distribution network, aiming for more extensive global use of its EVO ICL technology [2].